Moscow’s Gamelei Center could register the world’s first coronavirus vaccine on August 12, Russia’s deputy health minister has revealed. Oleg Gridnev says medical workers and the elderly will be given priority for immunization.
The senior minister at the department, Mikhail Murashko, announced last week that a nationwide mass vaccination program is planned to begin in October. Murashko added that all expenses will be covered by the government.
“The registration of the vaccine developed at the Gamelei Center will take place on August 12,” Gridnev told journalists in Ufa on Friday morning, as cited by RIA Novosti. “Now the last stage, the third, is underway. This is the testing part and is extremely important. We have to understand that the vaccine itself must be safe.”
The Health Ministry, in an official statement, clarified that “the documents required for registration of the vaccine developed by the Gamelei Center, including data from clinical trials, are under examination. The issue of its registration will be decided upon the results of the examination.”
Clinical trials of the formula began at Moscow’s Sechenov University on June 18. In a study involving 38 volunteers, it passed safety protocols. It was observed that all those who took part developed immunity to the infection.
The speed with which Russia has managed to research and approve a formula has raised some eyebrows in the West, but Vadim Tarasov, a top scientist at Sechenov, said the country had a head start as it has spent the last 20 years developing skills in this field and trying to understand how viruses transmit.
The haste is fairly easy to grasp when you consider the effect Covid-19 has had on the world’s largest country. With more than 870,000 cases, it is among the four countries worst affected by the epidemic, along with the US, Brazil, and India. Russia’s 14,725 fatalities is the 11th highest in the world, although when measured per capita, the death rate ranks 47th, below Germany, but above Austria.
The technology behind the Russian vaccine is based on adenovirus, the common cold. Created artificially, the vaccine proteins replicate those of Covid-19, triggering “an immune response similar to that caused by the coronavirus itself,” Tarasov said. In other words, immunization is similar to having survived the virus, but without its life-threatening risks.
English 